BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 17011058)

  • 1. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Chauvet B; Félix-Faure C; Davin JL; Berger C; Vincent P; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
    Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
    J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
    Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
    Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Poortmans PM; Richaud P; Collette L; Ho Goey S; Pierart M; Van Der Hulst M; Bolla M;
    Acta Oncol; 2008; 47(5):937-40. PubMed ID: 18568488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
    Hussain MH; Glass TR; Forman J; Sakr W; Smith DC; Al-Sarraf M; Jones J; Balcerzak SP; Crawford ED; Grossman HB
    J Urol; 2001 Jan; 165(1):56-60; discussion 60-1. PubMed ID: 11125363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.
    Azuma H; Kotake Y; Yamamoto K; Sakamoto T; Kiyama S; Ubai T; Inamoto T; Takahara K; Matsuki M; Segawa N; Shibahara N; Katsuoka Y
    Am J Clin Oncol; 2008 Feb; 31(1):11-21. PubMed ID: 18376222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: a report on patient compliance and acute toxicity.
    Serkies K; Jassem J
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):814-21. PubMed ID: 15465198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraarterial infusion of cisplatin with and without preoperative concurrent radiation for urinary bladder cancer: a preliminary report.
    Monzen Y; Mori H; Matsumoto S; Takaki H; Yoshida S; Wakisaka M; Ueda S; Mizoguchi H; Ogata J; Kato Y
    Radiat Med; 1995; 13(3):149-52. PubMed ID: 7569009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
    Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
    Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy?].
    Chrétien Y; Mejean A; Durdux C; Dufour B; Housset M
    J Urol (Paris); 1996; 102(1):3-8. PubMed ID: 8763598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
    Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
    J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.